Teva Prepared to Fight Charges in Generics Probe If Talks Fail - Bloomberg
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
FDA Approves Generic Version Of Teva's Blockbuster Drug - Drug Discovery and Development
Teva files potential blockbuster migraine drug for FDA approval
Report: Teva Suffers Migraine Over Express Scripts Drug Exclusion - Pharmaceutical Processing World
Teva's Blockbuster Drug Takes Another Generic Blow | Ctech
Teva Pharmaceuticals to lay off 14,000 employees worldwide, 1,750 in Israel - The Jerusalem Post
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches :: Scrip
Teva buys Allergan: 3 reasons why it's a blockbuster deal | Fortune
Teva Pharmaceutical Stock: Gem Among Generic Pharma Companies (NYSE:TEVA) | Seeking Alpha
A determined FDA takes down Teva's blockbuster | Evaluate
Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
Generic-drug maker Teva steals market share from Big Pharma - Aug. 5, 2009
TEVA stock on watch after EU approval for biosimilar to Roche's Lucentis (NYSE:TEVA) | Seeking Alpha
Pharma giant Teva looks to steady ship with new CEO in coming weeks | The Times of Israel
EU antitrust authorities launch probe of Teva over Copaxone drug | The Times of Israel
Cramer: Avoid This Drug Stock
Teva Pharmaceutical Stock Could Double | Barron's
Declining sales of blockbuster drug drag Teva revenue lower - MarketWatch
Teva to cut 14,000 jobs | Business | Chemistry World
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters
Teva bullish ahead of 2-step biosimilar attack on AbbVie's blockbuster Humira
Roche's Ocrevus achieves blockbuster status - Pharmaceutical Technology
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Silver Spring-based United Therapeutics settles patent dispute over Remodulin generic with Teva Pharmaceuticals - Washington Business Journal
